ADAURA Study Demonstrates Promising Efficacy for Osimertinib in EGFR-Mutant NSCLC

October 19, 2020

Masahiro Tsuboi, MD, discusses the key takeaways from the findings for osimertinib in patients with early-stage EGFR-mutant non–small cell lung cancer following a complete tumor resection in the phase 3 ADAURA clinical trial.

Hot Topics of Discussion in the Management of Multiple Myeloma

October 11, 2020

Jens Hillengass, MD, discusses the key takeaways from his presentation at the 2020 National Comprehensive Cancer Network Virtual Congress: Hematologic Malignancies, in which he shared his insights on the diagnostic and staging criteria in multiple myeloma.